Welcome to Raystarbio!Focus On Forefront Bioactive Compounds.
Find Your Distributors

Select Your Country or Region


You are here:Home-Research Areas-Inflammation/Autoimmune Disease-Psoriasis

Request The Product List ofPsoriasis Psoriasis

    Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal. This makes the skin build up into bumpy red patches covered with white scales. They can grow anywhere, but most appear on the scalp, elbows, knees, and lower back. Psoriasis can't be passed from person to person. It does sometimes happen in members of the same family.

get the basics on psoriasis

    Psoriasis usually appears in early adulthood. For most people, it affects just a few areas. In severe cases, psoriasis can cover large parts of the body. The patches can heal and then come back throughout a person's life.

Cat. No. Product Name CAS No. Information



Apremilast (CC-10004) is a potent, orally active PDE4 inhibitor with IC50 of 74 nM, inhibits TNF-α production in LPS-stimulated hPBMCs with IC50 of 77 nM; inhibits PBMC production of the chemokines CXCL9 and CXCL10, IFN-gamma and TNF-alpha, and IL-2, IL-12 and IL-23, also inhibits TNF-α by NK cells and keratinocytes; significantly reduces epidermal thickness and proliferation, decreases the general histopathological appearance of psoriasiform features and reduces expression of TNF-α, human leukocyte antigen-DR and intercellular adhesion molecule-1 in the lesioned skin in model of psoriasis.




GSK-2982772 is a potent, selective, ATP competitive RIP1 kinase inhibitor with IC50 of 16 nM; inhibits RIP1-dependent inflammatory cytokine MIP-1β production in human whole blood with IC50 of 0.5 nM, reduces spontaneous production of cytokines (IL-1β and IL-6) in a concentration-dependent fashion from ulcerative colitis explant tissue; shows potential for the treatment of inflammatory diseases in vivo.




A potent, selective JAK1 inhibitor for the treatment of psoriasis, lupus, and ulcerative colitis.




GSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM; shows no effects on RORα-dependent activation; robustly inhibits RORγ-mediated cytokine production at both the mRNA and protein level, inhibits RORγt-mediated transactivation; attenuates inflammation in mouse model of psoriasis.




Delgocitinib (JTE-052, LEO 124249) is a potent, selective, orally active, pan-JAK inhibitor with IC50 of 2.8, 2.6, 13 and 58 nM for JAK1,2,3 and Tyk2, respectively; does not inhibit a broad panel of kinases with exception of ROCK-II (IC50=140 nM); inhibits cytokine signaling evoked by IL-2, IL-6, IL-23, granulocyte/macrophage CSF, and IFN-α in vitro; potently suppresses the IL-2-induced IFN-γ production in mice (ED50=1.1 mg/kg), suppresses inflammatory responses in collagen-induced arthritis model.




PF-06263276 (PF06263276, PF 6263276) is a potent, selective pan JAK inhibitor with IC50 of 2.2, 23.1, 59.9 and 29.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively; demonstrates good JAK potency and kinase selectivity, exhibts inhibitory potency in human whole blood versus various stimulatory cytokines (IFNα, IL-23, IL-4, IL-6 and GM-CSF) with IC50 of 0.6-5.2 uM; suitable for inhaled and topical delivery in vivo.


PF-06700841 tosylate


PF-06700841 tosylate is a potent, selective TYK2/JAK1 kinase inhibitor that reduces IL-23 expression and directly attenuates IL-23 signaling via TYK2; is under investigation for the treatment of plaque psoriasis and lupus erythematosus.




PF-06700841 tosylate is a potent, selective TYK2/JAK1 kinase inhibitor that reduces IL-23 expression and directly attenuates IL-23 signaling via TYK2; is under investigation for the treatment of plaque psoriasis and lupus erythematosus.




VX-148 is a potent, uncompetitive, orally bioavailable IMPDH inhibitor with Ki of 6 nM against IMPDH type II enzyme; VX-148 is slightly more potent than VX-497 in inhibiting the proliferation of mitogen-stimulated primary human lymphocytes (IC50=80 nM); inhibits primary antibody response in mice with ED50 value of 38 mg/kg b.i.d, significantly prolongs skin graft survival at 100 mg/kg b.i.d.




Benvitimod is a natural aryl hydrocarbon receptor (AhR) agonist with anti-inflammatory properties; binds and activates AhR in multiple cell types, moderates proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impacts barrier gene expression in primary human keratinocytes; shows no impact on imiquimod-induced skin inflammation in AhR-deficient mice.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 RayStarBio. All Rights Reserved. Products are only for research use